文献速递神经肌肉病神经免疫神经重症与神经感染

抗PD-1单抗相关神经肌肉不良事件:系统综述

Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review.
PubMed 文献 · Neurology · 2019-03-08

症状以眼肌(47%)、呼吸(43%)、延髓(35%)和近端无力(35%)为主,诊断分类为重症肌无力(27%)、神经病(23%)、肌病(34%)或混合(16%)。尽管采用糖皮质激素、IVIG和血浆置换治疗,死亡率仍高,且重症肌无力或肌炎患者中心脏并发症超过30%。

要点

  • PD-1抑制剂相关神经肌肉不良事件表现常不典型,重症肌无力与肌病重叠明显。
  • 眼肌、呼吸、延髓和近端无力是常见症状,肌痛见于28%患者。
  • 重症肌无力或肌炎患者心脏并发症发生率超过30%,死亡率高。

核心结论

  • PD-1抑制剂相关神经肌肉不良事件表现常不典型,重症肌无力与肌病重叠,心脏/呼吸并发症常见且死亡率高。

研究设计与样本

  • 患者平均年龄66.9岁(范围34-86),男女比2.6:1,59%为转移性黑色素瘤。

主要发现

  • 症状包括眼肌(47%)、呼吸(43%)、延髓(35%)、近端无力(35%)和肌痛(28%)。
  • 诊断分类为重症肌无力(27%)、神经病(23%)、肌病(34%)或混合(16%)。
  • 经 critical review 后,13%病例的NMD诊断证据不足,高达25%患者存在其他NMD体征。
  • 重症肌无力或肌炎患者中心脏并发症超过30%,死亡率高。

临床怎么用

  • 对接受PD-1抑制剂治疗的患者应警惕不典型的神经肌肉症状,尤其是眼肌、呼吸和延髓受累。
  • 重症肌无力或肌炎患者需监测心脏和呼吸并发症。
  • 尽管使用糖皮质激素、IVIG和血浆置换,死亡率仍高,需早期识别和积极管理。

局限性

  • 系统综述基于已发表文献,可能存在发表偏倚。
  • 13%病例的NMD诊断证据不足,25%患者存在其他NMD体征,诊断准确性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neuromuscular adverse events following cancer treatment with anti-programmed cell death protein 1 (PD-1) monoclonal antibodies are relatively rare, yet potentially fatal. We performed a systematic review to characterize the clinical presentation, diagnostic workup, and management of neuromuscular disorders (NMDs) in patients treated with nivolumab or pembrolizumab monotherapy or concurrent with other immunologic agents, such as ipilimumab. Sixty-one publications on 85 patients (mean age 66.9 years [range 34-86]; male/female 2.6:1; 59% metastatic melanoma) were identified from selected indexing databases until June 2018. Forty-eight patients had received nivolumab and 39 pembrolizumab. The mean number of PD-1 inhibitor treatment cycles prior to onset of symptoms was 3.6 (range 1-28). Symptoms included oculomotor (47%), respiratory (43%), bulbar (35%), and proximal weakness (35%), as well as muscle pain (28%). Diagnoses were categorized as myasthenia gravis (27%), neuropathy (23%), myopathy (34%), or a combination of these (16%). After a critical review of the data, however, evidence did not support the stated NMD diagnosis in 13% of cases, while up to 25% of patients had signs of additional NMDs. Cardiac complications occurred in more than 30% of patients diagnosed with myasthenia gravis or myositis. Mortality was high in these patients, despite adequate treatment strategies including corticosteroid, IV immunoglobulins, and plasma exchange. The clinical presentation of NMDs associated with PD-1 inhibitors is often atypical, with considerable overlap between myasthenia gravis and myopathy, and cardiac/respiratory complications are common.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Johansen A, Christensen SJ, Scheie D, et al. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review. Neurology. 2019. PMID: 30850443. doi:10.1212/WNL.0000000000007235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。